COA in PROgress
The development of a patient-centric strategy in clinical research
Apr 21, 2024
Patient-centered drug development expert Sonya Eremenco and clinical research specialist John Powers discuss the importance of putting patients at the heart of COA approaches in clinical research, from concept to endpoint positioning. They explore the significance of aligning COA strategy with patient priorities, measuring disease attributes, and consulting patients early to determine key measures for improved participation and relevant metrics.
31:16
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Developing a patient-centered drug development strategy involves understanding the significance of clinical outcome assessments (COAs) for measuring patient experiences and outcomes.
- Engaging with patients during the early stages of strategy development helps prioritize essential measurements and select appropriate outcome measures.
Deep dives
Importance of Defining COAs and COA Strategy
Developing a patient-centered drug development strategy involves understanding the significance of clinical outcome assessments (COAs). COAs are crucial for measuring how patients feel, function, and survive, assessing clinical benefit based on patient experiences. The strategy must encompass different types of COAs such as patient-reported outcome measures and clinical relevance to treatment impact. A strategic approach focuses on patient priorities, disease progression, and treatment effects to align with patient needs and treatment outcomes.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
